ALPA

Alpa Laboratories Limited

Pharmaceutical manufacturer under Drugs & Chemicals segment

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

alpalabs.in(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹53.46
Market cap
112 Cr
Stock P/E
32.2
P/B
0.60
ROE (FY26)
7.6%
ROCE (FY26)
8.5%
Operating margin (FY26)
1.1%
Debt / equity (FY26)
0.01
OCF / EBITDA (FY26)
324.0%
OCF / EBITDA (3Y)
132.3%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Alpa Laboratories makes and sells pharmaceutical products (drugs and chemicals).

Company snapshot

112thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓132% of operating profit came in as cash over the last three years — profits are backed by real cash.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales32 Cr27 Cr24 Cr21 Cr25 Cr26 Cr40 Cr19 Cr26 Cr29 Cr31 Cr24 Cr
Operating expenses (approx.)29 Cr25 Cr20 Cr21 Cr22 Cr25 Cr40 Cr19 Cr28 Cr28 Cr28 Cr28 Cr
EBITDA3 Cr2 Cr4 Cr0.53 Cr3 Cr0.74 Cr0.20 Cr0.42 Cr-2 Cr2 Cr4 Cr-4 Cr
OPM %10.4%8.9%14.9%2.5%13.3%2.8%0.5%2.2%-8.5%5.2%11.5%-16.5%
Other income3 Cr4 Cr4 Cr5 Cr7 Cr9 Cr2 Cr12 Cr3 Cr0.91 Cr-0.16 Cr6 Cr
Interest0.02 Cr0.02 Cr0.29 Cr0.05 Cr0.05 Cr0.09 Cr0.02 Cr0.05 Cr0.03 Cr0.03 Cr0.15 Cr0.11 Cr
Depreciation0.49 Cr0.66 Cr0.52 Cr0.54 Cr0.53 Cr0.55 Cr0.58 Cr0.55 Cr0.67 Cr0.65 Cr0.22 Cr0.72 Cr
Profit before tax6 Cr5 Cr7 Cr5 Cr10 Cr9 Cr2 Cr12 Cr0.11 Cr2 Cr2 Cr0.98 Cr
Tax %0.0%14.9%46.7%0.0%20.4%0.0%202.4%0.0%0.0%-8.9%77.2%0.0%
Net profit6 Cr5 Cr4 Cr5 Cr8 Cr9 Cr-2 Cr12 Cr0.11 Cr2 Cr0.50 Cr0.98 Cr
EPS (₹)₹2.75₹2.17₹1.71₹2.42₹3.66₹4.23₹-0.95₹5.59₹0.05₹0.90₹0.24₹0.49

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales63 Cr63 Cr78 Cr86 Cr98 Cr112 Cr92 Cr109 Cr112 Cr106 CrSign in free for the trailing twelve months
Operating expenses (approx.)56 Cr59 Cr77 Cr83 Cr90 Cr102 Cr85 Cr101 Cr108 Cr103 CrSign in free for the trailing twelve months
EBITDA7 Cr4 Cr1 Cr3 Cr8 Cr11 Cr8 Cr8 Cr5 Cr3 CrSign in free for the trailing twelve months
OPM %11.2%6.7%1.5%3.9%7.9%9.5%8.2%7.5%4.2%3.1%Sign in free for the trailing twelve months
Other income5 Cr5 Cr5 Cr3 Cr4 Cr11 Cr10 Cr15 Cr23 Cr16 CrSign in free for the trailing twelve months
Interest2 Cr1 Cr0.57 Cr0.20 Cr0.08 Cr0.24 Cr0.22 Cr0.36 Cr0.23 Cr0.26 CrSign in free for the trailing twelve months
Depreciation3 Cr3 Cr3 Cr3 Cr1 Cr2 Cr1 Cr2 Cr2 Cr2 CrSign in free for the trailing twelve months
Profit before tax6 Cr5 Cr3 Cr3 Cr11 Cr20 Cr16 Cr21 Cr26 Cr16 CrSign in free for the trailing twelve months
Tax %55.3%39.8%63.3%36.3%32.8%28.0%20.7%18.9%24.0%10.7%Sign in free for the trailing twelve months
Net profit3 Cr3 Cr1 Cr2 Cr7 Cr14 Cr13 Cr17 Cr20 Cr14 CrSign in free for the trailing twelve months
EPS (₹)₹1.20₹1.33₹0.00₹0.89₹3.45₹6.67₹5.90₹8.01₹9.34₹6.71Sign in free for the trailing twelve months
Dividend payout %————0.0%0.0%0.0%0.0%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital21 Cr21 Cr21 Cr21 Cr21 Cr21 Cr21 Cr21 Cr21 Cr21 Cr
Reserves74 Cr76 Cr77 Cr79 Cr87 Cr101 Cr114 Cr131 Cr150 Cr165 Cr
Borrowings11 Cr6 Cr1 Cr0.19 Cr0.0091 Cr6 Cr2 Cr5 Cr—3 Cr
Other liabilities20 Cr18 Cr21 Cr21 Cr33 Cr28 Cr31 Cr25 Cr51 Cr53 Cr
Total liabilities126 Cr121 Cr121 Cr121 Cr140 Cr155 Cr167 Cr183 Cr223 Cr242 Cr
Fixed assets (net)5 Cr6 Cr6 Cr6 Cr7 Cr9 Cr7 Cr11 Cr21 Cr20 Cr
CWIP——0.12 Cr0.81 Cr2 Cr0 Cr0 Cr0 Cr0 Cr0 Cr
Investments13 Cr31 Cr49 Cr57 Cr51 Cr75 Cr78 Cr98 Cr118 Cr142 Cr
Loans & advances———0.99 Cr0.77 Cr0.54 Cr0.56 Cr0.57 Cr0.54 Cr0.53 Cr
Inventories13 Cr14 Cr14 Cr13 Cr17 Cr15 Cr13 Cr14 Cr18 Cr13 Cr
Trade receivables29 Cr26 Cr30 Cr25 Cr35 Cr38 Cr47 Cr41 Cr47 Cr41 Cr
Cash & bank2 Cr0.19 Cr0.15 Cr5 Cr2 Cr2 Cr9 Cr0.06 Cr0.03 Cr0.64 Cr
Other assets63 Cr45 Cr23 Cr14 Cr26 Cr16 Cr13 Cr17 Cr19 Cr25 Cr
Total assets126 Cr121 Cr121 Cr121 Cr140 Cr155 Cr167 Cr183 Cr223 Cr242 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity17 Cr2 Cr-1 Cr18 Cr-2 Cr2 Cr-5 Cr4 Cr7 Cr11 Cr
Cash from investing-2 Cr-12 Cr-15 Cr-11 Cr6 Cr-16 Cr1 Cr-13 Cr-1 Cr-12 Cr
Cash from financing-15 Cr-6 Cr-5 Cr-1 Cr-0.03 Cr6 Cr-3 Cr3 Cr-5 Cr2 Cr
Net cash flow0.04 Cr-15 Cr-20 Cr5 Cr4 Cr-8 Cr-7 Cr-7 Cr0.48 Cr0.62 Cr
Free cash flow (OCF − Capex)16 Cr-0.14 Cr-2 Cr15 Cr-5 Cr-0.21 Cr-6 Cr-3 Cr-4 Cr7 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %7.0%5.5%3.3%3.1%10.1%15.5%11.8%13.4%15.1%8.5%
ROE %2.7%2.9%1.0%1.8%6.7%11.6%9.4%11.0%11.4%7.6%
Debtor days167151140104132123184139152140
Inventory days139151110931118984799177
Days payable148146103101166861006896102
Cash conversion cycle1581561479677127168150146115
OCF / EBITDA %239.0%43.8%n.m.529.9%-19.6%18.6%-64.1%45.0%148.5%324.0%
OCF / EBITDA % (3 years)——143.1%214.0%125.2%84.0%-16.8%3.0%28.7%132.3%
Debt / equity0.110.060.010.00190.00010.050.020.03—0.01
Current ratio———4.593.704.424.985.694.104.01
Net debt / EBITDA1.161.331.15-1.43-0.230.40-0.860.64-0.00560.57